Work

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

Year: 2013

Type: article

Source: Xenobiotica

DOI: 10.3109/00498254.2013.831143

Authors: May Y. K. Ho, Michael J. Morris, Jill L. Pirhalla, John W. Bauman, Carolyn B. Pendry, Keith W. Orford, Royce A. Morrison, Donna S. Cox

Institution: GlaxoSmithKline (United States)

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2028058432

FWCI: 3.025

Cites: 28

Cited by: 26

Related to: 10